TY - JOUR
T1 - Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome
AU - The RIS Study Group
AU - Fissolo, Nicolás
AU - Schaedelin, Sabine
AU - Villar, Luisa M.
AU - Lünemann, Jan D.
AU - Correale, Jorge
AU - Rejdak, Konrad
AU - Schwab, Nicholas
AU - Vilaseca, Andreu
AU - Held, Friederike
AU - García-Merino, Antonio
AU - Bittner, Stefan
AU - Trojano, María
AU - Furlan, Roberto
AU - Tumani, Hayrettin
AU - Pérez-Miralles, Francisco
AU - Rosenstein, Igal
AU - Galimberti, Daniela
AU - Álvarez-Bravo, Gary
AU - Thouvenot, Eric
AU - Llufriu, Sara
AU - Khoury, Samia J.
AU - Hoepner, Robert
AU - Martínez-Yélamos, Sergio
AU - Hegen, Harald
AU - Drulovic, Jelena
AU - Téllez-Lara, Neus
AU - Khalil, Michael
AU - Oechtering, Johanna
AU - Pérez-Sempere, Ángel
AU - Rodríguez-Antigüedad, Alfredo
AU - Enrique-Martínez, José
AU - Strijbis, Eva
AU - Killestein, Joep
AU - Eichau, Sara
AU - Colombo, Elena
AU - Schaller-Nagengast, Jonas
AU - Midaglia, Luciana
AU - Sánchez-López, Antonio J.
AU - Monreal, Enric
AU - Chan, Andrew
AU - Paul, Friedemann
AU - Rovira, Àlex
AU - Tintoré, Mar
AU - Lycke, Jan
AU - Zipp, Frauke
AU - Hemmer, Bernhard
AU - Kuhle, Jens
AU - Montalban, Xavier
AU - Comabella, Manuel
N1 - Publisher Copyright:
© 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2025/7
Y1 - 2025/7
N2 - IMPORTANCE Understanding the risk factors for symptom development will allow clinicians to stratify people with radiologically isolated syndrome (pwRIS) more effectively and tailor their management strategies accordingly. OBJECTIVE To identify prognostic factors at radiologically isolated syndrome (RIS) diagnosis associated with the development of multiple sclerosis (MS) symptoms. DESIGN, SETTING, AND PARTICIPANTS This cohort study was performed in samples collected between July 2004 and September 2022 and included 33 MS centers. All pwRIS who meet the 2017 McDonald criteria for dissemination in space with a sample collected near the diagnostic magnetic resonance imaging were included. No patients who met eligibility criteria were excluded. The data were analyzed from July 2024 to November 2024. EXPOSURE Body fluid biomarkers and environmental factors in pwRIS. MAIN OUTCOMES AND MEASURES The main outcome was the development of MS symptoms. Analyses involved univariable and multivariable Cox proportional hazards models, including age, sex, and treatment following RIS diagnosis, as additional independent variables. RESULTS The study included 273 pwRIS (mean age, 38.6 [SD 11.6] years; 207 women [75.8%] and 66 men [24.2%]) with a median follow-up of 5.0 [IQR, 2.5-7.7] years. A total of 101 pwRIS developed MS symptoms (37.0%). The presence of immunoglobulin G oligoclonal bands (OBs) (hazard ratio [HR], 5.09; 95% CI, 2.36-10.97; P < .001), immunoglobulin M OBs (HR, 2.58; 95% CI, 1.61-4.14; P < .001), and a κ free light chain index of 6.1 or more (HR, 2.79; 95% CI, 1.37-5.67; P = .005) were associated with MS symptoms. High cerebrospinal fluid neurofilament light chain (NfL) levels (HR, 1.31; 95% CI, 1.18-1.45; P < .001) and high serum NfL z scores (HR, 1.42; 95% CI, 1.16-1.72; P = .005) were also associated with an increased risk of MS symptoms. In contrast, high anti-cytomegalovirus titers (HR, 0.59; 95% CI, 0.38-0.93; P = .02) and high ultraviolet radiation exposure in the year before (HR, 0.52; 95% CI, 0.37-0.74; P < .001) and the year after (HR, 0.54, 95% CI, 0.38-0.75; P < .001) diagnosis reduced the risk of MS symptoms. For all these prognostic factors, the multivariable analysis yielded similar results. The combination of high serum NfL z scores and positive immunoglobulin G OBs conferred a 5-year risk of clinical symptoms of 58.3% (95% CI, 45.9-67.9). This risk increased to 81.6% (95% CI, 60.9-91.4) in pwRIS who were younger and positive for immunoglobulin M OBs. CONCLUSIONS AND RELEVANCE The study elucidates the prognostic factors that significantly impact the risk of developing MS symptoms in pwRIS at diagnosis, thereby, enhancing the potential for tailored clinical interventions.
AB - IMPORTANCE Understanding the risk factors for symptom development will allow clinicians to stratify people with radiologically isolated syndrome (pwRIS) more effectively and tailor their management strategies accordingly. OBJECTIVE To identify prognostic factors at radiologically isolated syndrome (RIS) diagnosis associated with the development of multiple sclerosis (MS) symptoms. DESIGN, SETTING, AND PARTICIPANTS This cohort study was performed in samples collected between July 2004 and September 2022 and included 33 MS centers. All pwRIS who meet the 2017 McDonald criteria for dissemination in space with a sample collected near the diagnostic magnetic resonance imaging were included. No patients who met eligibility criteria were excluded. The data were analyzed from July 2024 to November 2024. EXPOSURE Body fluid biomarkers and environmental factors in pwRIS. MAIN OUTCOMES AND MEASURES The main outcome was the development of MS symptoms. Analyses involved univariable and multivariable Cox proportional hazards models, including age, sex, and treatment following RIS diagnosis, as additional independent variables. RESULTS The study included 273 pwRIS (mean age, 38.6 [SD 11.6] years; 207 women [75.8%] and 66 men [24.2%]) with a median follow-up of 5.0 [IQR, 2.5-7.7] years. A total of 101 pwRIS developed MS symptoms (37.0%). The presence of immunoglobulin G oligoclonal bands (OBs) (hazard ratio [HR], 5.09; 95% CI, 2.36-10.97; P < .001), immunoglobulin M OBs (HR, 2.58; 95% CI, 1.61-4.14; P < .001), and a κ free light chain index of 6.1 or more (HR, 2.79; 95% CI, 1.37-5.67; P = .005) were associated with MS symptoms. High cerebrospinal fluid neurofilament light chain (NfL) levels (HR, 1.31; 95% CI, 1.18-1.45; P < .001) and high serum NfL z scores (HR, 1.42; 95% CI, 1.16-1.72; P = .005) were also associated with an increased risk of MS symptoms. In contrast, high anti-cytomegalovirus titers (HR, 0.59; 95% CI, 0.38-0.93; P = .02) and high ultraviolet radiation exposure in the year before (HR, 0.52; 95% CI, 0.37-0.74; P < .001) and the year after (HR, 0.54, 95% CI, 0.38-0.75; P < .001) diagnosis reduced the risk of MS symptoms. For all these prognostic factors, the multivariable analysis yielded similar results. The combination of high serum NfL z scores and positive immunoglobulin G OBs conferred a 5-year risk of clinical symptoms of 58.3% (95% CI, 45.9-67.9). This risk increased to 81.6% (95% CI, 60.9-91.4) in pwRIS who were younger and positive for immunoglobulin M OBs. CONCLUSIONS AND RELEVANCE The study elucidates the prognostic factors that significantly impact the risk of developing MS symptoms in pwRIS at diagnosis, thereby, enhancing the potential for tailored clinical interventions.
UR - https://www.scopus.com/pages/publications/105007097515
U2 - 10.1001/jamaneurol.2025.1481
DO - 10.1001/jamaneurol.2025.1481
M3 - Article
AN - SCOPUS:105007097515
SN - 2168-6149
VL - 82
SP - 722
EP - 733
JO - JAMA Neurology
JF - JAMA Neurology
IS - 7
ER -